Fresenius Kabi SwissBioSim GmbH

Fresenius Kabi SwissBioSim GmbH is a pharmaceutical company headquartered in Eysins, Switzerland, and operates as a subsidiary within the broader Fresenius Kabi group. Fresenius Kabi, in turn, is a key business segment of the publicly traded German healthcare conglomerate Fresenius SE & Co. KGaA (Frankfurt Stock Exchange: FRE). The parent Fresenius company was founded in 1912, and the Else Kröner-Fresenius-Stiftung is its largest shareholder, holding 27% of the shares. Fresenius Kabi generates $8B-$9B in revenue, contributing to the parent company's market capitalization of approximately $18B.

The company specializes in the research, development, and commercialization of biosimilars, which are high-quality, affordable alternatives to existing biologic therapies. Fresenius Kabi SwissBioSim's portfolio and pipeline focus on critical therapeutic areas, including immunology, oncology, rheumatology, endocrinology, gastroenterology, dermatology, hematology, and osteoporosis. Examples of their FDA-approved biosimilars include Conexxence® and Bomyntra® (denosumab biosimilars), Idacio® (adalimumab), Otulfi™ (ustekinumab), Stimufend® (pegfilgrastim), and Tyenne® (tocilizumab).

In terms of patent litigation, Fresenius Kabi SwissBioSim GmbH operates as an assertive entity, primarily engaging as a plaintiff to challenge patents related to reference biologic products. The company has one tracked case, appearing solely as a plaintiff and with no cases as a defendant. This posture is consistent with an operating company actively seeking to clear intellectual property pathways for its biosimilar product offerings.

The sole tracked case, Fresenius Kabi SwissBioSim GmbH v. Regeneron Pharmaceuticals, Inc., is a plaintiff-side action adjudicated at the Patent Trial and Appeal Board (PTAB). This type of proceeding typically involves challenging the validity of existing patents, likely in preparation for or support of launching a biosimilar version of a Regeneron biologic.